amphetamine ER Mydayis
Selected indexed studies
- MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. (Nat Med, 2021) [PMID:33972795]
- AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. (Gastroenterology, 2022) [PMID:36273831]
- Amphetamine. (, 2006) [PMID:30000366]
_Worker-drafted node — pending editorial review._
Connections
amphetamine ER Mydayis is a side effect of
Sources
- Amphetamine. (2006) pubmed
- Extended-Release Mixed Amphetamine Salts for Comorbid Adult Attention-Deficit/Hyperactivity Disorder and Cannabis Use Disorder: A Pilot, Randomized Double-Blind, Placebo-Controlled Trial. (2024) pubmed
- Recent advances in pharmacological management of attention-deficit/hyperactivity disorder: moving beyond stimulants. (2024) pubmed
- MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. (2021) pubmed
- Pediatric attention deficit hyperactivity disorder (ADHD): 2022 updates on pharmacological management. (2023) pubmed
- AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. (2022) pubmed
- Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome. (2021) pubmed
- Neurotoxicity of methamphetamine: Main effects and mechanisms. (2021) pubmed
- Assessment of centanafadine in adults with attention-deficit/hyperactivity disorder: A matching-adjusted indirect comparison vs lisdexamfetamine dimesylate, atomoxetine hydrochloride, and viloxazine extended-release. (2024) pubmed
- How dangerous is MDMA? (2022) pubmed